GENECAI

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 10 Oct 2025 filing date already counts against anyone who files later.

Record

Serial number

99436972

Mark type

Stylized text

Filed

10 Oct 2025

Published for opposition

17 Feb 2026

Attorney of record

Isaac M. Fine

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for alleviating side effects of cancer treatments; Pharmaceutical preparations for alleviating side effects of chemotherapy; Pharmaceutical preparations for alleviating side effects of radiation therapy; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for alleviating side effects of immunotherapy treatments; Pharmaceutical preparations for alleviating gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for stimulating appetite; Pharmaceutical preparations for preventing weight loss; Pharmaceutical preparations for protecting bone marrow and the production of bone marrow; Pharmaceutical preparations for protecting stem cells and stimulating the production of stem cells; Pharmaceutical preparations for increasing resiliency of stem cells, increasing the number of stem cells, and preventing the reduction of stem cell populations; Pharmaceutical preparations for protecting blood cells, alleviating anemia, neutropenia, thrombocytopenia, and alleviating low blood counts; Pharmaceutical preparations for alleviating dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of side effects of cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of chemotherapy; Pharmaceutical preparations for the prevention and treatment of side effects of radiation therapy; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for the prevention and treatment of side effects of immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for the prevention and treatment of loss of appetite; Pharmaceutical preparations for the prevention and treatment of weight loss; Pharmaceutical preparations for the treatment and prevention of bone marrow damage; Pharmaceutical preparations for the treatment and prevention of stem cell damage and reduction of stem cell populations; Pharmaceutical preparations for the treatment and prevention of blood cell damage, anemia, and low blood count; Pharmaceutical preparations for the treatment and prevention of dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the treatment and prevention of side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments, namely, reduced fertility; Pharmaceutical preparations for supporting stem cell health and production; Pharmaceutical preparations for supporting stem cell health and production, namely for stimulating uterine, bone marrow and gastrointestinal track stem cell production; Pharmaceutical preparations for the treatment of radiation exposure; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of inflammatory bowel disease, ulcerative colitis and other inflammatory bowel disorders; Pharmaceutical preparations for the enhancement of chemotherapy; Pharmaceutical preparations for the enhancement of immunotherapy; Fertility enhancement preparations

Owner

• Caper Labs, Inc., San Francisco, CA, US
• Caper Labs, Inc., San Francisco, CA, US

Prosecution history

• 17 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 17 Feb 2026 — PUBLISHED FOR OPPOSITION
• 11 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 23 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 21 Jan 2026 — ASSIGNED TO EXAMINER
• 12 Dec 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 12 Dec 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 12 Dec 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 10 Oct 2025 — APPLICATION FILING RECEIPT MAILED
• 10 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 10 Oct 2025 — NEW APPLICATION ENTERED